Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Markovic

Showing results (331-340 of 368) with videos related to

Pageof 37
Sort By:
Blood|February 4, 2016
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionSaad Sirop Kenderian, Thomas M Habermann, William R Macon, et al.
JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Bowel perforation in intestinal lymphoma: incidence and clinical featuresR Vaidya, T M Habermann, J H Donohue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from MelanomaUgur Sener, Mason Webb, William G Breen, et al.
JCO Precision Oncology|October 26, 2023
Plasma Methylated DNA Markers for Melanoma SurveillanceCalise K Berger, William R Taylor, Douglas W Mahoney, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Pageof 37

Showing results (331-340 of 368) with videos related to

Sort By:
Pageof 37
Blood|February 4, 2016
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionSaad Sirop Kenderian, Thomas M Habermann, William R Macon, et al.
JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Bowel perforation in intestinal lymphoma: incidence and clinical featuresR Vaidya, T M Habermann, J H Donohue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from MelanomaUgur Sener, Mason Webb, William G Breen, et al.
JCO Precision Oncology|October 26, 2023
Plasma Methylated DNA Markers for Melanoma SurveillanceCalise K Berger, William R Taylor, Douglas W Mahoney, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Pageof 37